Is enzalutamide suitable for patients with advanced prostate cancer?

Enzalutamide is an oral androgen receptor antagonist mainly used to treat patients with advanced prostate cancer, especially those who have developed castration-resistant prostate cancer (CRPC). Castration-resistant prostate cancer is a condition in which prostate cancer continues to progress despite castration treatments (such as endocrine therapy or decreased testosterone levels), often with the expansion of the malignancy.

Enzalutamide inhibits the stimulating effect of androgens on prostate cancer cells by blocking the signaling pathway of androgen receptors, thereby inhibiting the growth of cancer cells. By binding directly to androgen receptors, it blocks the effects of the hormone and prevents cancer cells from continuing to grow and spread. Due to the important role of androgen receptors in prostate cancer cells, enzalutamide has become one of the key drugs in the treatment of advanced prostate cancer.

Enzalutamide is effective in patients with advanced prostate cancer, especially castration-resistant prostate cancer. Multiple clinical studies have shown that enzalutamide can significantly improve progression-free survival (PFS) and overall survival (OS), and effectively alleviate patients' symptoms. It is approved for the treatment of patients with castration-resistant prostate cancer and can be used as first-line treatment or after chemotherapy.

However, enzalutamide is not suitable for all patients with advanced prostate cancer. Enzalutamide should be used with caution in patients with severe hepatic impairment. In addition, enzalutamide may also cause some side effects, such as fatigue, dizziness, high blood pressure, epilepsy, etc. Therefore, patients should regularly monitor their health conditions under the guidance of a doctor when using this drug.

xa0